Q3 2024

Filed Nov 5, 2024 · 10-Q · 36 days after period end · 0000950170-24-121439

Q3 2024 · 10-Q

Revenue

$12.50M

— vs Q3 2023

Net Income

-$84.13M

N/M vs Q3 2023

EPS Diluted

-$0.98

N/M vs Q3 2023

Operating Income-$89,577,000N/M

Operating Cash Flow

Same quarter

Metric	Q3 2024	Q3 2023	Q3 2022	Q3 2021
Revenue	$12.50M	$0.00	—	$12.38M
Net Income	-$84.13M	-$51.15M	-$35.40M	-$20.64M
EPS Diluted	-$0.98	-$0.73	-$0.58	-$0.40

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR